PortfoliosLab logoPortfoliosLab logo

Documentation

Upgrade your plan
IDNA vs. XLV
Performance
Return for Risk
Dividends
Drawdowns
Volatility

IDNA vs. XLV

Last updated Apr 2, 2026

Compare and contrast key facts about iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA) and State Street Health Care Select Sector SPDR ETF (XLV).

IDNA and XLV are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. IDNA is a passively managed fund by iShares that tracks the performance of the NYSE FactSet Global Genomics and Immuno Biopharma Index. It was launched on Jun 11, 2019. XLV is a passively managed fund by State Street that tracks the performance of the Health Care Select Sector Index. It was launched on Dec 16, 1998. Both IDNA and XLV are passive ETFs, meaning that they are not actively managed but aim to replicate the performance of the underlying index as closely as possible.

Performance

IDNA vs. XLV - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA) and State Street Health Care Select Sector SPDR ETF (XLV). The values are adjusted to include any dividend payments, if applicable.

Loading graphics...

IDNA vs. XLV - Yearly Performance Comparison

2026 (YTD)2025202420232022202120202019
IDNA
iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund		11.45%17.26%-0.72%-7.63%-42.28%-3.98%54.30%20.83%
XLV
State Street Health Care Select Sector SPDR ETF		-4.18%14.50%2.47%2.07%-2.08%26.04%13.30%13.51%

Returns By Period

In the year-to-date period, IDNA achieves a 11.45% return, which is significantly higher than XLV's -4.18% return.

IDNA

1D
0.48%
1M
-5.56%
YTD
11.45%
6M
20.68%
1Y
48.06%
3Y*
9.03%
5Y*
-7.93%
10Y*
—

XLV

1D
0.76%
1M
-6.43%
YTD
-4.18%
6M
3.83%
1Y
4.90%
3Y*
6.25%
5Y*
6.59%
10Y*
9.80%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund

State Street Health Care Select Sector SPDR ETF

Often compared with IDNA:
IDNA vs. ARKGIDNA vs. GNOMIDNA vs. PBEIDNA vs. IBBIDNA vs. HELXIDNA vs. XGEN.DEIDNA vs. IBBQ
Often compared with XLV:
XLV vs. VHTXLV vs. SPYXLV vs. XLFXLV vs. IXJXLV vs. FHLCXLV vs. VOOXLV vs. UNH

IDNA vs. XLV - Expense Ratio Comparison

IDNA has a 0.47% expense ratio, which is higher than XLV's 0.08% expense ratio.

IDNA
iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund
XLV
State Street Health Care Select Sector SPDR ETF

Return for Risk

IDNA vs. XLV — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.
IDNA
IDNA Risk / Return Rank: 8585
Overall Rank
IDNA Sharpe Ratio Rank: 8585
Sharpe Ratio Rank
IDNA Sortino Ratio Rank: 8686
Sortino Ratio Rank
IDNA Omega Ratio Rank: 7474
Omega Ratio Rank
IDNA Calmar Ratio Rank: 9393
Calmar Ratio Rank
IDNA Martin Ratio Rank: 8888
Martin Ratio Rank
XLV
XLV Risk / Return Rank: 1818
Overall Rank
XLV Sharpe Ratio Rank: 1919
Sharpe Ratio Rank
XLV Sortino Ratio Rank: 1818
Sortino Ratio Rank
XLV Omega Ratio Rank: 1818
Omega Ratio Rank
XLV Calmar Ratio Rank: 1717
Calmar Ratio Rank
XLV Martin Ratio Rank: 1616
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

IDNA vs. XLV - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA) and State Street Health Care Select Sector SPDR ETF (XLV). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

IDNAXLVDifference

Sharpe ratio

Return per unit of total volatility

1.75

0.28

+1.47

Sortino ratio

Return per unit of downside risk

2.40

0.51

+1.89

Omega ratio

Gain probability vs. loss probability

1.29

1.06

+0.22

Calmar ratio

Return relative to maximum drawdown

3.66

0.28

+3.38

Martin ratio

Return relative to average drawdown

11.65

0.58

+11.06

Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

IDNA vs. XLV - Sharpe Ratio Comparison

The current IDNA Sharpe Ratio is 1.75, which is higher than the XLV Sharpe Ratio of 0.28. The chart below compares the historical Sharpe Ratios of IDNA and XLV, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Loading graphics...

Sharpe Ratios by Period

IDNAXLVDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

1.75

0.28

+1.47

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.28

0.45

-0.73

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

—

0.59

—

Sharpe Ratio (All Time)

Calculated using the full available price history

0.11

0.46

-0.35

Correlation

The correlation between IDNA and XLV is 0.56, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.

Dividends

IDNA vs. XLV - Dividend Comparison

IDNA's dividend yield for the trailing twelve months is around 1.06%, less than XLV's 1.70% yield.

TTM20252024202320222021202020192018201720162015
IDNA
iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund		1.06%1.18%0.98%1.04%0.54%0.70%0.26%0.80%0.00%0.00%0.00%0.00%
XLV
State Street Health Care Select Sector SPDR ETF		1.70%1.60%1.67%1.59%1.47%1.33%1.49%2.17%1.57%1.47%1.60%1.43%

Drawdowns

IDNA vs. XLV - Drawdown Comparison

The maximum IDNA drawdown since its inception was -68.26%, which is greater than XLV's maximum drawdown of -39.17%. Use the drawdown chart below to compare losses from any high point for IDNA and XLV.

Loading graphics...

Drawdown Indicators

IDNAXLVDifference

Max Drawdown

Largest peak-to-trough decline

-68.26%

-39.17%

-29.09%

Max Drawdown (1Y)

Largest decline over 1 year

-12.11%

-10.76%

-1.35%

Max Drawdown (5Y)

Largest decline over 5 years

-68.26%

-17.11%

-51.15%

Max Drawdown (10Y)

Largest decline over 10 years

—

-28.40%

—

Current Drawdown

Current decline from peak

-45.05%

-7.41%

-37.64%

Average Drawdown

Average peak-to-trough decline

-36.05%

-7.12%

-28.93%

Ulcer Index

Depth and duration of drawdowns from previous peaks

3.81%

5.11%

-1.30%

Volatility

IDNA vs. XLV - Volatility Comparison

iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA) has a higher volatility of 9.54% compared to State Street Health Care Select Sector SPDR ETF (XLV) at 4.79%. This indicates that IDNA's price experiences larger fluctuations and is considered to be riskier than XLV based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Loading graphics...

Volatility by Period

IDNAXLVDifference

Volatility (1M)

Calculated over the trailing 1-month period

9.54%

4.79%

+4.75%

Volatility (6M)

Calculated over the trailing 6-month period

18.22%

10.29%

+7.93%

Volatility (1Y)

Calculated over the trailing 1-year period

27.75%

17.73%

+10.02%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

28.53%

14.56%

+13.97%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

29.68%

16.53%

+13.15%